文献速递糖尿病性腺与生殖内分泌

女性糖尿病患者生殖生命周期中的血糖波动

Glucose excursions throughout the reproductive life stages in women with diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2026-09-15

本综述汇总1型和2型糖尿病女性在青春期、月经周期、生育治疗、妊娠及绝经期的血糖波动证据。青春期胰岛素敏感性生理性下降,月经周期雌孕激素变化影响胰岛素抵抗但数据多来自1型糖尿病,妊娠期胰岛素抵抗显著而CGM和自动胰岛素输注系统改善母婴结局,绝经期雌激素下降致胰岛素抵抗增加而MHT可能改善血糖。女性在代谢研究中长期代表性不足,未来需整合CGM与激素谱分析。

要点

  • 青春期胰岛素敏感性生理性下降叠加行为神经认知因素,导致血糖异常和心血管代谢风险增加。
  • 妊娠期胰岛素抵抗显著,CGM和自动胰岛素输注系统应整合进孕前和孕期管理以改善母婴结局。
  • 绝经期雌激素下降而雄激素相对保留致胰岛素抵抗增加,MHT可能改善血糖但1型糖尿病证据有限。

核心结论

  • 女性糖尿病患者在整个生殖生命周期经历显著的胰岛素敏感性波动,但临床管理指南仍有限。
  • 女性在代谢研究中长期代表性不足,阻碍了基于证据的激素驱动血糖波动管理策略的开发。

研究设计与样本

  • 本综述综合了1型和2型糖尿病女性在青春期、月经周期、生育治疗、妊娠和绝经期等关键激素过渡阶段的代谢影响证据。

主要发现

  • 青春期以胰岛素敏感性生理性下降为特征,叠加行为神经认知因素,促成血糖异常和心血管代谢风险增加。
  • 雌二醇和孕酮的周期性变化影响月经周期中的胰岛素抵抗,但现有数据主要涉及1型糖尿病,2型糖尿病存在重大知识缺口。
  • 妊娠是胰岛素抵抗显著的时期,糖尿病技术进步特别是CGM和自动胰岛素输注系统改善了母亲血糖控制和新生儿结局。
  • 绝经期雌激素下降和雄激素相对保留促成胰岛素抵抗增加,MHT可能改善血糖但1型糖尿病证据有限。
  • 生育治疗日益普遍,理解卵巢刺激对血糖的影响愈发重要,但当前证据仍然稀少。

临床怎么用

  • CGM和自动胰岛素输注系统应整合进孕前和孕期护理以改善母婴结局。
  • MHT可能改善绝经期血糖,但需考虑1型糖尿病证据有限。
  • 生育治疗中应关注卵巢刺激对血糖的影响。

局限性

  • 现有月经周期数据主要涉及1型糖尿病,2型糖尿病存在重大知识缺口。
  • 生育治疗对血糖影响的当前证据仍然稀少。
  • MHT改善血糖的证据在1型糖尿病中有限。
  • 女性在代谢研究中长期代表性不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Women with diabetes experience substantial fluctuations in insulin sensitivity across the reproductive lifespan, yet clinical guidance on managing these glycemic challenges remains limited. This review synthesizes current evidence on the metabolic impact of key hormonal transitions, including puberty, the menstrual cycle, fertility treatment, pregnancy, and menopause, in women with type 1 (T1DM) and type 2 diabetes (T2DM). Puberty is marked by a physiological decline in insulin sensitivity compounded by behavioral and neurocognitive factors, contributing to dysglycemia and increased cardiometabolic risk. Cyclical variations in estradiol and progesterone influence insulin resistance across the menstrual cycle, but existing data predominantly concern T1DM, leaving major knowledge gaps for T2DM. As fertility treatment becomes more common, understanding the glycemic effects of ovarian stimulation is increasingly important, though current evidence remains sparse. Pregnancy represents a period of pronounced insulin resistance, but advances in diabetes technology, particularly continuous glucose monitoring (CGM) and automated insulin delivery systems, have improved maternal glycemic control and neonatal outcomes and should be integrated into preconception and pregnancy care. In menopause, declining estrogen and relatively preserved androgen levels contribute to increased insulin resistance; menopausal hormone therapy (MHT) may improve glycemia, though evidence in T1DM is limited. Across all life stages, the historical underrepresentation of women in metabolic research has hindered development of evidence-based strategies for managing hormonally driven glucose excursions. Future studies integrating CGM with detailed hormonal profiling, particularly in women with T2DM and those undergoing fertility treatment or MHT, are essential to optimize diabetes care throughout the female lifespan.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Knorr S, Knudsen TS, Kirkegaard K, et al. Glucose excursions throughout the reproductive life stages in women with diabetes. J Clin Endocrinol Metab. 2026. PMID: 42740693. doi:10.1210/clinem/dgag379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。